We are thrilled to share an important development for the spinal muscular atrophy (SMA) community. The U.S. Food and Drug Administration (FDA) has approved Novartis’ Itvisma® offering a new treatment option for children aged 2 and older, as well as teens and adults living with SMA.
This approval marks a significant step forward, reflecting decades of research, innovation, and collaboration within the neuromuscular field. Itvisma expands therapeutic choices for families and individuals affected by SMA, reinforcing the progress being made toward improving care and outcomes.
Read the press release here: https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-itvisma-only-gene-replacement-therapy-children-two-years-and-older-teens-and-adults-spinal-muscular-atrophy-sma
